<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004975</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongCHI006</org_study_id>
    <nct_id>NCT04004975</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib</brief_title>
  <official_title>Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit
      tumor angiogenesis and inhibit tumor cell growth. We performed second-generation gene
      sequencing on pathological specimens and cerebrospinal fluid of patients with recurrent
      glioblastoma.If patients have a genetic mutation （VEGFR，Kit，PDGFR，FGFR）and meet other
      eligibility criteria, they will be treated with antroinib. The initial observation targets
      were progression-free survival and adverse reactions. The secondary objective was overal
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INCLUSION CRITERIA:

        1. Histologically confirmed World Health Organization (WHO) Grade IV glioblastoma.;

        2. Radiographic evidence of tumour progression or recurrence;

        3. The second-generation gene sequencing on pathological specimens and cerebrospinal fluid
           show at least one genetic mutation of the four genes (VEGFR，Kit，PDGFR，FGFR);

        4. ≥ 18 years of age;

        5. Karnofsky performance status (KPS) ≥ 70;

        6. Corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan.

        7. a new baseline scan is required 1.7 Measurable disease as per Response Assessment in
           Neuro-Oncology (RANO) criteria;

        8. Estimated survival of at least 3 months;

        9. signed informed consent form;

       10. Hgb &gt; 9 gm; absolute neutrophil count (ANC) &gt; 1500/μl; platelets &gt; 100,000; Creatinine &lt;
           1.5 times the upper limit of laboratory normal value; Bilirubin &lt; 2 times the upper
           limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum
           glutamate oxaloacetate transaminase (SGOT) &lt; 3 times the upper limit of laboratory
           normal value;

      EXCLUSION CRITERIA:

      Exclusion Criteria:

        1. Subjects with newly diagnosed GBM

        2. Pregnant women or nursing mothers cannot participate in the study. Women of childbearing
           age must have a negative pregnancy test within 72 hours prior to study entry. Women of
           childbearing potential must practice medically approved contraceptive precautions;

        3. Abnormal hematological results at inclusion with: Neutrophils &lt; 1,500/mm3;
           Blood-platelets &lt; 100,000/mm3

        4. Severe or chronic renal insufficiency (creatinine clearance ≤ 30 ml/min);

        5. Patient unable to follow procedures, visits, examinations described in the study;

        6. Any usual formal indication against imaging examinations (important claustrophobia,
           pacemaker);
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2019</start_date>
  <completion_date type="Anticipated">July 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>one-armed controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>each 42 days up to PD or death(up to 24 months)</time_frame>
    <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
    <description>OS is defined as the time until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score (QoL)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>use EORTC QLQ-C30(version 3) questionnaire to evaluate the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg daily from day 1 to 14 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.</description>
    <arm_group_label>anlotinib</arm_group_label>
    <other_name>Fu Ke Wei</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed World Health Organization (WHO) Grade IV glioblastoma.;

          2. Radiographic evidence of tumour progression or recurrence;

          3. The second-generation gene sequencing on pathological specimens and cerebrospinal
             fluid show at least one genetic mutation of the four genes (VEGFR，Kit，PDGFR，FGFR);

          4. ≥ 18 years of age;

          5. Karnofsky performance status (KPS) ≥ 70;

          6. Corticosteroid dose must be stable or decreasing for at least 5 days prior to the
             scan.

          7. a new baseline scan is required 1.7 Measurable disease as per Response Assessment in
             Neuro-Oncology (RANO) criteria;

          8. Estimated survival of at least 3 months;

          9. signed informed consent form;

         10. Hgb &gt; 9 gm; absolute neutrophil count (ANC) &gt; 1500/μl; platelets &gt; 100,000; Creatinine
             &lt; 1.5 times the upper limit of laboratory normal value; Bilirubin &lt; 2 times the upper
             limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or
             serum glutamate oxaloacetate transaminase (SGOT) &lt; 3 times the upper limit of
             laboratory normal value;

        Exclusion Criteria:

          1. Subjects with newly diagnosed GBM

          2. Pregnant women or nursing mothers cannot participate in the study. Women of
             childbearing age must have a negative pregnancy test within 72 hours prior to study
             entry. Women of childbearing potential must practice medically approved contraceptive
             precautions;

          3. Abnormal hematological results at inclusion with: Neutrophils &lt; 1,500/mm3;
             Blood-platelets &lt; 100,000/mm3

          4. Severe or chronic renal insufficiency (creatinine clearance ≤ 30 ml/min);

          5. Patient unable to follow procedures, visits, examinations described in the study;

          6. Any usual formal indication against imaging examinations (important claustrophobia,
             pacemaker);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rongjie Tao, Dr.</last_name>
    <phone>13969191909</phone>
    <email>rongjietao@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Xu, Dr.</last_name>
    <phone>6762312</phone>
    <email>doctorwy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shandong cancer hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongjie Tao, Dr.</last_name>
      <phone>13969191909</phone>
      <email>rongjietao@13.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, Luo Y, Zhang Y, Huang C, Li Q, Wu G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.</citation>
    <PMID>29438373</PMID>
  </reference>
  <results_reference>
    <citation>Syed YY. Anlotinib: First Global Approval. Drugs. 2018 Jul;78(10):1057-1062. doi: 10.1007/s40265-018-0939-x. Review. Erratum in: Drugs. 2018 Aug;78(12):1287.</citation>
    <PMID>29943374</PMID>
  </results_reference>
  <results_reference>
    <citation>Lv Y, Zhang J, Liu F, Song M, Hou Y, Liang N. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review. Medicine (Baltimore). 2019 May;98(22):e15749. doi: 10.1097/MD.0000000000015749. Review.</citation>
    <PMID>31145289</PMID>
  </results_reference>
  <results_reference>
    <citation>Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120. doi: 10.1186/s13045-018-0664-7. Review.</citation>
    <PMID>30231931</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Rongjie Tao</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>anlotinib Recurrent Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

